"A MTX PG3 less than 30 nmol/L in a child who has failed to respond within 12 weeks suggests that an increase in oral dose, or even a change to subcutaneous [administration], will boost efficacy," she commented.
Mr. Rahman, Dr. Siegfried, and Dr. Paller reported having no relevant financial disclosures.